Grünenthal invests in e-mobility at headquarters in Aachen

Aachen, Germany (ots) - Grünenthal, a global leader in pain management and
related diseases, has announced it will now include electric and hybrid engines
in the fleet of company cars for managers at its site in Aachen, Germany. The
decision is part of the company's ongoing commitment to promoting sustainability
by reducing the environmental footprint of its operations. And it also marks the
latest step forward in its long tradition of investing in future-facing
technologies.

By making this transition to low-carbon vehicles - including models from Tesla
and e.GO, an eCar manufacturer headquartered in Aachen - the company is
responding to the growing market trend, while also reflecting the increasingly
strong public focus on environmental responsibility. Several charging stations
will be created on the company's premises to make sure employees are always able
to recharge their vehicles while they work. These stations will offer a
significant amount of free charging time and will be available for all employees
to use, including those who do not have a company car.

As a science-based and family-owned company, Grünenthal is committed to driving
progress towards sustainable development by minimising its environmental
footprint and investing in resource-efficient technologies. The decision to
include hybrid and electric vehicles in its fleet of company cars for managers
is just the latest step in the company's ongoing efforts in this regard, and
stands alongside its focus on continuously improving efficiency and occupational
safety, while also cutting waste. The company is now considering further
opportunities to extend the offer to other countries and sites where the local
infrastructure and required financial investment make it feasible.

"Our company has always taken a long-term and science-focused approach to our
business operations," says Gabriel Baertschi, CEO Grünenthal. "By including
electric and hybrid vehicles in our company car fleet in Aachen, we're investing
in innovative and sustainable technology that will support our contribution to
protecting our planet - and help us take another step forward in our commitment
to continuously reducing our environmental footprint."

About Grünenthal

Grünenthal is a global leader in pain management and related diseases. As a
science-based, privately-owned pharmaceutical company, we have a long track
record of bringing innovative treatments and state-of-the-art technologies to
patients worldwide. Our purpose is to change lives for the better - and
innovation is our passion. We are focussing all of our activities and efforts on
working towards our vision of a world free of pain.

Grünenthal is headquartered in Aachen, Germany, and has affiliates in 30
countries across Europe, Latin America and the US. Our products are available in
more than 100 countries. In 2018, Grünenthal employed around 4,900 people and
achieved sales of EUR 1.3 bn.

More information: www.grunenthal.com (www.grunenthal.com)

Follow us on:
LinkedIn: Grunenthal Group
Twitter: @grunenthalgroup
Instagram: grunenthal

For further information please contact:

Stepan Kracala, Head Global Communications
Phone: +49 241 569-1335, Stepan.Kracala@grunenthal.com
Grünenthal GmbH, 52099 Aachen, Germany

Additional content: https://www.presseportal.de/pm/118252/4510584
OTS: Grünenthal Group

Original-Content von: Grünenthal Group, übermittelt durch news aktuell